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OBJECTIVES We sought to evaluate the diagnostic accuracy and feasibility of bedside pacing stress
echocardiography (PASE) as a potential substitute for pharmacologic stress echocardiography
in patients admitted to the hospital with new-onset chest pain or worsening angina pectoris.
BACKGROUND Accurate and rapid noninvasive identification and evaluation of the extent of coronary artery
disease (CAD) is essential for optimal management of these patients.
METHODS Bedside transthoracic stress echocardiography was performed in 54 consecutive patients
admitted to a community hospital with new-onset chest pain, after acute myocardial
infarction had been excluded. We used 10F transesophageal pacing catheters and a rapid and
modified pacing protocol. The PASE results were validated in all patients by coronary
angiography performed within 24 h of the test. Significant CAD was defined as $75%
stenosis in at least one major epicardial coronary artery.
RESULTS The sensitivity of PASE for identifying patients with significant CAD was 95%, specificity
was 87% and accuracy was 92%. The extent of significant CAD (single- or multivessel
disease) was highly concordant with coronary angiography (kappa 5 0.73, p , 0.001). Pacing
stress echocardiography was well tolerated, and only 4% of the patients had minor adverse
events. The mean rate–pressure product at peak pacing was 22,313 6 5,357 beats/min per
mm Hg, and heart rate .85% of the age-predicted target was achieved in 94% of patients.
The average duration of the bedside PASE test, including image interpretation, was 38 6
6 min.
CONCLUSIONS Bedside PASE is rapid, tolerable and accurate for identification of significant CAD in
patients admitted to the hospital with new-onset chest pain or worsening angina pectoris.
(J Am Coll Cardiol 2000;36:1935–41) © 2000 by the American College of Cardiology
Pharmacologic stress echocardiography, mainly using do-
butamine, is frequently used for the detection, localization
and estimation of the severity of myocardial ischemia (1–4).
Optimally, noninvasive cardiac imaging tests should be
rapid, safe, feasible, highly accurate and cost-effective (1,2).
However, dobutamine stress echocardiography (DSE) is
time-consuming and may be associated with a high fre-
quency of side effects, such as hypotension, atrial and
ventricular arrhythmia, tremor and nausea (4–6). In addi-
tion, pharmacologic stress testing may not be feasible for all
patients owing to contraindications to its use (5,6).
Relatively little data are available on the use of trans-
esophageal atrial pacing in combination with transthoracic
echocardiography, as compared with standard methods of
cardiac stress testing. Previously published studies suggest
that pacing stress echocardiography (PASE) is a safe and
accurate method for the detection of coronary artery disease
(CAD) in outpatients and for the evaluation of patients
early after myocardial infarction (7–15). More recently, it
has been shown that the diagnostic accuracy of PASE in
outpatients compares favorably with DSE, and that PASE
is as tolerable as DSE (16). We therefore examined the
utility of bedside PASE and a rapid and modified pacing
protocol as a potential substitute for pharmacologic stress
echocardiography in patients admitted to the hospital with
new-onset chest pain or worsening angina pectoris.
METHODS
Study patients. The hospital’s Institutional Review Board
approved the study, and all patients gave informed consent.
Fifty-four consecutive patients admitted to the Cardiac
Intensive Care Unit or Cardiac Observation Unit who
agreed to undergo PASE as well as coronary angiography
within 24 h were included in the study. Inclusion criteria
were 1) new-onset chest pain, clinically suspected to be
ischemic in origin; and 2) no enzymatic (troponin I or
creatine kinase and creatine kinase, MB fraction) or elec-
trocardiographic (ECG) evidence of a new myocardial
infarction. Exclusion criteria were 1) known esophageal
disease; 2) atrial fibrillation or advanced heart block; 3)
moderate or severe valvular aortic stenosis; and 4) an
International Normalized Ratio of .2.5. We did not
exclude patients from evaluation if they had a previous
myocardial infarction, cardiomyopathy, complete bundle
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branch block on the baseline ECG or baseline echocardio-
graphic wall motion abnormalities. To assess the practical
utility of PASE, we included patients even if they had
suboptimal two-dimensional echocardiographic image qual-
ity. The patients were all tested after fasting for at least 4 h.
Feasibility of PASE. The feasibility of PASE was evalu-
ated by the following variables: rapidity, safety and tolera-
bility. The time elapsed from the beginning of technical
preparations to the end of the study (including study image
interpretation) was recorded. Adverse events were catego-
rized as minor (transient atrial arrhythmia, vomiting) or
major (ventricular tachycardia, ECG changes compatible
with evolution of acute myocardial infarction, worsening of
heart failure or esophageal perforation).
Immediately after termination of pacing, the patients
were asked to grade their level of discomfort and the
tolerability of the test on a scale of 1 to 10 (1 5 intolerable;
10 5 not causing any discomfort).
Transesophageal atrial pacing protocol. The studies were
performed at the patient’s bedside. Noninvasive blood
pressure was measured by an automatic device and recorded
every 2 min. Heart rate was continuously monitored
throughout the study. A twelve-lead ECG was performed at
baseline, at peak heart rate and immediately after pacing.
An ischemic response on the ECG was defined as $0.1 mV
horizontal or downsloping ST segment depression at 80 ms
after the J point in at least two contiguous leads at peak
pacing heart rate. Chest pain, any associated symptoms and
side effects were recorded during the test.
Transesophageal atrial pacing was performed with the
Tapstress pacing system and Tapscope 10F transesophageal
bipolar pacing catheters (model 7A of the transesophageal
cardiac stimulator and model 3 of the recording preampli-
fier, Cardiocommand, Tampa, Florida). Before insertion of
the pacing catheter, the patients were given a local anes-
thetic spray (20% benzocaine, Hurricane, Beutlich, Wauke-
gan, Illinois). The pacing catheter tip was covered with
lubricating jelly (K-Y, Johnson & Johnson, Arlington,
Texas). Intravenous sedation (midazolam, 1 mg) was offered
to patients who were anxious before the procedure. The
patients were asked to lie in the left lateral recumbent
position. The pacing catheter was inserted through the
oropharynx to the esophagus to the 40-cm mark by instruct-
ing the patient to swallow, and then it was withdrawn until
a 1:1 capture of atrial/ventricular activity was achieved.
Pacing was then started at a rate of 120 beats/min (pulse
width 10 ms, output current 20 mA), and the pacing rate
was increased within 30 s to a target heart rate calculated as
equal to 220 2 age. Echocardiographic imaging was started
after constant pacing at peak heart rate was achieved. Pacing
and echocardiographic imaging were discontinued immedi-
ately after all myocardial segments were imaged in the five
conventional transthoracic echocardiographic views
(parasternal long- and short-axis, as well as apical four-,
two- and three-chamber views). Other end points to the
PASE test were severe angina, systolic blood pressure
.240 mm Hg or ,90 mm Hg, diastolic blood pressure
.120 mm Hg or intolerable symptoms. The pacing output
current was adjusted during the test to decrease the patient’s
discomfort to a minimum, while allowing for continuous
and stable pacing. Patients sustaining second-degree
Wenckebach atrioventricular block during pacing were
given intravenous atropine, 0.4 to 2 mg, as necessary, in
0.4-mg increments every 30 s until 1:1 capture was
achieved.
Echocardiographic imaging. Transthoracic echocardiog-
raphy was performed with tissue harmonic imaging (P4-2
transducer, HDI 5000, ATL, Bothell, Washington; and
3.5-MHz transducer, Sequoia, Acuson, Mountain View,
California). We compared baseline images (before pacing)
with peak pacing images and postpacing images acquired
5 min after termination of pacing. The studies were inter-
preted by a consensus of three experienced readers who had
no knowledge of the patients’ clinical profile or ECG
tracings during or after the test. For interpretation of the
studies, we used the 16-segment model as adopted by the
American Society of Echocardiography (17). Wall motion
was graded as 1 5 normal; 2 5 hypokinetic; 3 5 akinetic;
and 4 5 dyskinetic. Segments were considered ischemic if a
new wall motion abnormality or worsening of preexisting
abnormalities of at least one grade was detected at the peak
pacing heart rate and returned to baseline wall motion in the
postpacing images. Segments with baseline abnormalities
that did not change in severity during pacing were evaluated
as nonischemic. The 16 echocardiographic myocardial seg-
ments were assigned to coronary vascular territories, as
suggested by Segar et al. (18).
Level of confidence. Each myocardial segment was inter-
preted by the readers according to a level of confidence
ranging from 100% to 0% (100% 5 very confident; 0% 5
unable to interpret), by assessing wall motion and wall
thickening. The level of confidence was divided to three
categories: high level of confidence ($90%); intermediate
(50% to 89%) and low (,50%). A PASE test had a high
level of confidence only if all three coronary vascular terri-
tories were interpreted with a high level of confidence.
Angiographic imaging. Coronary angiography was per-
formed with biplane acquisition (Advantex, GE Medical
System, Wakeshaw, Wisconsin). The angiograms were
interpreted by a consensus of three experienced readers
using a semiquantitative grading system (0%, 25%, 50%,
75%, 99% or 100% diameter stenosis), as recommended by
the American Heart Association (19). The readers had no
knowledge of the results of the PASE test. Significant CAD
Abbreviations and Acronyms
CAD 5 coronary artery disease
DSE 5 dobutamine stress echocardiography
ECG 5 electrocardiography
PASE 5 pacing stress echocardiography
SPECT 5 single-photon emission computed tomography
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was defined as lumen diameter stenosis $75%. As in other
studies assessing the utility of stress echocardiography for
the detection of CAD (14,16,20,21), we also have analyzed
our data using $50% lumen diameter stenosis for defining
significant CAD. The results of this analysis are presented
in the Results section.
Validation of study results by myocardial single-photon
emission computed tomography (SPECT). The patients
underwent myocardial SPECT within 24 h (usually within
3 h) after performing PASE. The protocol used for myo-
cardial SPECT was previously described by Berman et al.
(22). A semiquantitative visual interpretation was performed
utilizing short-axis and vertical long-axis myocardial tomo-
grams and a 20-segment model, as previously described
(22). The method of assignment of tomographic myocardial
segments to vascular territories was performed as previously
described (23). The abnormal vascular territories, as iden-
tified by PASE, were then compared with the assignment of
segments to vascular territories by SPECT.
Statistical analysis. We correlated PASE and coronary
angiography for 1) the presence or absence of significant
CAD; and 2) the extent and location of myocardial ischemia
by coronary vascular territories. The results are presented
using the definition of lesion diameter stenosis $75% to
represent significant CAD, unless stated otherwise. The
kappa coefficient was used for agreement and concordance
analysis. Continuous measures are expressed as the mean
value 6 SD. Mean differences for continuous variables were
compared using the paired Student t test. A p value ,0.05
was considered significant.
RESULTS
Fifty-four consecutive patients (21 women, 33 men; age
66 6 10 years [range 40 to 85]) were studied. The patients’
characteristics are presented in Table 1. We were unable to
perform pacing in one patient. In the other 53 patients, the
mean total duration of the test, including technical prepa-
rations and interpretation of the echocardiographic images,
was 38 6 6 min, with a median time of 35 min (range 30 to
60). The mean duration of pacing was 6.6 6 2.6 min, with
a median time of 6 min. Midazolam was administered to
8 patients (15%). Intravenous atropine, 0.4 to 2 mg, was
administered to 21 patients (40%, average dose 0.8 mg)
sustaining second-degree Wenckebach atrioventricular
block during pacing.
Feasibility of bedside PASE. Pacing stress echocardiog-
raphy was completed in all patients enrolled except for one.
In this patient, we were unable to get any atrial capture. One
patient who received 0.8 mg of atropine developed su-
praventricular tachycardia during pacing and was subse-
quently treated successfully with intravenous adenosine.
Another patient vomited at the end of the test. No other
adverse events were noted. The mean tolerability score, as
graded by the patients immediately after the end of the
PASE test, was 8.3 6 1.1 (on a scale of 1 to 10), with a
median score of 9.
Hemodynamic data. Of 53 patients, 50 (94%) achieved
$85% of their predicted target heart rate (220 2 age), and
34 patients (64%) were paced to .95% of their target heart
rate. The mean baseline heart rate was 70 6 13 beats/min,
and the peak heart rate achieved was 149 6 12 beats/min
(p , 0.0001). The mean baseline systolic blood pressure was
142 6 23 mm Hg, and the mean peak systolic blood
pressure achieved was 149 6 29 mm Hg (p 5 0.0003). In
34 patients (64%), there was a mean increase of 19 6
13 mm Hg in systolic blood pressure. In one patient (2%),
there was no change in systolic blood pressure, and in
18 patients (34%), there was a mean drop in blood pressure
of 15 6 15 mm Hg. For the entire cohort (n 5 53), the
mean rate–pressure product achieved at peak pacing heart
rate was 22,313 6 5,357 beats/min per mm Hg.
Diagnostic accuracy of PASE. In 49 of 53 patients, the
PASE findings were concordant with the findings of coro-
nary angiography (92% accuracy). There were 36 patients
with true positive and 13 patients with true negative results.
Two patients had false positive PASE, and two had a false
negative test. Table 2 presents PASE results for identifying
patients with significant CAD, as well as the results for
specific vascular territories. The sensitivity of PASE for
identifying patients with significant CAD was 95%, and the
specificity was 87%. The negative predictive value of the test
was 87%, and the positive predictive value was 95%. Table
3 summarizes the concordance of PASE test and coronary
angiography by the extent of CAD. In 44 (83%) of
53 patients, there was full concordance of the PASE test
and coronary angiography with regard to the extent of
significant CAD (kappa 5 0.73, p , 0.001). Overall, the
PASE test overestimated the extent of significant CAD in
five patients (9%) and underestimated the extent of signif-
icant CAD in four patients (7%).
Analysis by level of confidence. In 46 (87%) of
53 patients, our level of confidence in interpreting all three
Table 1. Patients Characteristics (n 5 54)
n (%)
Age (years) 64 6 10
Gender (F/M) 21/33 (39%/61%)
Diabetes mellitus 19 (35%)
Systemic hypertension 34 (63%)
Hyperlipidemia 34 (63%)
Smoking 19 (35%)
Family history of CAD 6 (11%)
Obesity 7 (13%)
$3 Risk factors for CAD 17 (31%)





Beta-blocker/calcium antagonist treatment 28 (52%)
Data are presented as the mean value 6 SD or number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease;
CVA 5 cerebrovascular accident; F 5 female; M 5 male; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty; PVD 5
peripheral vascular disease.
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coronary vascular territories for identifying inducible seg-
mental myocardial ischemia by PASE was graded as high
(.90%). In these 46 patients, the accuracy, sensitivity and
specificity of PASE were all 97%. In seven patients, the level
of confidence in interpreting any coronary vascular territory
was intermediate (50% to 89%). For the entire study group,
25 (3%) of 848 echocardiographic myocardial segments
were interpreted with an intermediate or low level of
confidence. The specific segments were as follow: basal
inferior wall (n 5 6), mid and apical inferior wall (n 5 6),
posterobasal interventricular septum (n 5 3), mid and distal
interventricular septum (n 5 2), basal and mid posterior
wall (n 5 2) and basal, mid and apical anterior wall (n 5 6).
Analysis of PASE results according to baseline wall
motion abnormalities. Thirty-one patients had normal
wall motion on baseline rest two-dimensional echocardiog-
raphy. Twenty-seven patients (87%) were correctly identi-
fied by PASE (16 as true positive, 11 as true negative). One
patient was falsely identified as positive, and two were falsely
identified as negative. As shown in Table 2, the sensitivity
of PASE in this group was 89%, specificity was 92% and
accuracy was 90%. The positive and negative predictive
values of PASE in patients with normal baseline echocar-
diograms were 94% and 85%, respectively. In the 22 patients
with abnormal rest wall motion (Table 2), the sensitivity of
PASE was 100%, yet the specificity was 67% and the
accuracy 95%.
Analysis of PASE for >50% lumen diameter stenosis.
We have also analyzed PASE accuracy for the detection of
CAD by defining significant CAD as $50% lumen diam-
eter stenosis. In the entire cohort, there were 14 coronary
arteries in 13 patients with $50% and ,75% lumen
diameter stenoses. When we considered these lesions to
represent significant CAD, 37 patients were now identified
by PASE as having true positive and 10 as having true
negative results (accuracy 89%, sensitivity 88% and specific-
ity 91%). The results of PASE using a definition of
significant CAD as either $50% or $75% diameter stenosis
are compared in Table 4.
Correlation with myocardial SPECT. Of the 54 patients
who underwent both PASE and coronary angiography, 16
also underwent myocardial SPECT within 24 h. The PASE
and myocardial SPECT results correlated in 15 of the
16 patients. The PASE and coronary angiographic results
correlated in 15 of these 16 patients. Fourteen patients had
complete concordance between angiography and positive
myocardial SPECT and PASE results. One patient had a
positive PASE and myocardial SPECT test but no signif-
icant lesions detected on angiography, whereas another
patient had a positive myocardial SPECT test but no
significant coronary angiographic lesions, which was con-
cordant with the normal PASE study. Using coronary
angiography as a gold standard, the sensitivity of PASE in
this subgroup was 93% and the specificity was 100%.
Electrocardiographic data. The baseline ECG was normal
in 31 patients (58%). Two patients (4%) had complete right
bundle branch block, two (4%) had complete left bundle
branch block, three (6%) had first-degree atrioventricular
block and four (7%) had evidence of left ventricular hyper-
trophy with a strain pattern. Electrocardiographic evidence
of a previous myocardial infarction was noted in 11 patients
(21%). New ischemic changes on the ECG ($1 mm ST
segment depression) during pacing were recorded in 16
patients (30%). One patient had ischemic ECG changes
and a normal coronary angiogram. The sensitivity of elec-
trocardiography at peak stress was 38%, the specificity was
89% and the accuracy was 43%.
Table 2. Accuracy, Sensitivity and Specificity of Pacing Stress Echocardiography
n
Patients LAD LCx RCA
Sens. Spec. Acc. Sens. Spec. Acc. Sens. Spec. Acc. Sens. Spec. Acc.
Cohort 53 95 87 92 96 89 92 82 97 91 81 81 81
Abnormal B/L 22 100 67 95 94 87 90 85 94 91 87 77 81
Normal B/L 31 89 92 90 100 94 97 78 100 93 70 86 80
*Accuracy, sensitivity and specificity are presented as percentages.
Acc. 5 accuracy; B/L 5 baseline two-dimensional echocardiography; cohort 5 entire group of patients; LCx 5 left circumflex coronary artery; LAD 5 left anterior descending
coronary artery; RCA 5 right coronary artery; Sens. 5 sensitivity; Spec. 5 specificity.
Table 3. Coronary Angiography
PASE Test NS SVD MVD Total
NS 13 2 0 15
SVD 0 8 2 10
MVD 2 3 23 28
Total 15 13 25 53
Concordance of PASE and coronary angiography for the extent of significant CAD
(kappa 5 0.73). As indicated by the boldface numbers, 44 (83%) of 53 patients were
correctly identified for the extent of significant CAD (13 without significant coronary
stenoses, 8 with single-vessel disease and 23 with multivessel disease). Pacing stress
echocardiography underestimated the extent of significant CAD in four patients (7%)
and overestimated it in five (9%). Data are presented as number of patients.
MVD 5 multivessel disease; NS 5 nonsignificant coronary stenoses; PASE 5
pacing stress echocardiography; SVD 5 single-vessel disease.




Sensitivity (%) 88 95
Specificity (%) 91 87
Accuracy (%) 89 92
Positive predictive value (%) 97 95
Negative predictive value (%) 67 87
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DISCUSSION
Lee et al. (16) from the Mayo Clinic were the first to
compare PASE and dobutamine pharmacologic stress echo-
cardiography for the detection of inducible myocardial
ischemia in outpatients with chronic stable angina. To our
knowledge, our study is the first to examine PASE as an
alternative to pharmacologic stress echocardiography for
rapid bedside identification of CAD in intermediate to high
risk patients admitted to the hospital with new-onset chest
pain or worsening angina pectoris.
Feasibility of PASE. In an intermediate to high risk group
of patients, we found PASE to be feasible and tolerable.
Only two patients (4%) had minor adverse events that
resolved shortly after termination of pacing, without further
medical consequences. This high degree of safety of trans-
esophageal atrial pacing is probably due to the ability to
terminate pacing immediately if any adverse events occur,
thus allowing the heart rate and myocardial oxygen con-
sumption to return immediately to the baseline level (6,12).
Despite its reported high accuracy, sensitivity and speci-
ficity, transesophageal atrial pacing has not been adopted as
a common method for cardiac stress induction. Previously,
transesophageal atrial pacing methods were poorly tolerated
owing to the nasal route of insertion of the pacing catheter,
as well as to the pacing stimulus itself (13,14). We believe
the improved tolerability in our study is related to 1) the use
of smaller, specially designed pacing catheters (10F instead
of 18F or transvenous pacing electrodes); 2) a modified and
rapid pacing protocol; and 3) the oral route of pacing
catheter insertion. Our “tolerability score” correlates with
the “acceptance score” recently published by Lee et al. (16)(8
on a scale of 10 and 4 on a scale of 5, respectively).
The mean duration of the bedside PASE test, including
technical preparations and image interpretation, was
38 min. This is significantly shorter than the durations in
other widely used noninvasive cardiac imaging modalities
(4,16). Although we did not exclude patients with subop-
timal echocardiographic images, PASE was feasible in
nearly all the patients enrolled, probably because of the use
of harmonic imaging, as well as the lack of an increase in the
respiratory rate or change in the magnitude of respiration
during PASE. Thus, bedside PASE has a high utility for
safe and rapid identification of significant coronary artery
stenoses in patients admitted to the hospital with new-onset
chest pain or worsening angina pectoris.
Diagnostic accuracy of PASE. We found PASE to have
an accuracy, sensitivity and specificity of 92%, 95% and
87%, respectively, for detecting patients with significant
CAD, as well as for detecting ischemic vascular territories.
Our findings indicate that PASE is also accurate in patients
with normal wall motion on rest echocardiography. These
patients have been previously noted to have a relatively low
sensitivity for the detection of CAD by stress echocardiog-
raphy (1). The possible etiologies for the false positive
results were not different from those encountered by other
echocardiographic stress tests (1). The accuracy, sensitivity
and specificity of PASE are similar or superior to those in
other validation studies of pharmacologic or exercise stress
echocardiography (2–4,24). Moreover, in a subgroup of
patients who underwent myocardial SPECT within 24 h of
the PASE test, in addition to coronary angiography, the
three methods correlated well. Thus, a “perfusion” gold
standard, as well as an anatomic gold standard, validated the
accuracy of PASE in our study.
It is well recognized that stenosis severity may affect the
sensitivity of stress echocardiography (21,25). Frequently, a
50% reduction in coronary artery diameter is used to define
significant CAD (1,14,16,21,25). Although coronary an-
giography is often used as a gold standard for identifying the
presence of significant CAD, there is some controversy and
inconsistency as to what constitutes a significant coronary
angiographic diameter stenosis—50%, 70%, or 75%? We
therefore wanted our data to be comparable to those of
other studies, whether they considered a 50% or 75%
diameter of coronary stenosis as significant. In the entire
cohort, there were 14 coronary arteries in 13 patients with
$50% and ,75% lumen diameter stenosis. Because of the
documented limitation in the precision of coronary angio-
graphic assessment of coronary obstruction of intermediate
severity (26–28), we separately analyzed lesions with $50%
and ,75% and those with $75% diameter stenosis. We
analyzed our data using either $50% or $75% diameter
stenosis to define significant CAD, and as presented in
Table 4, we found PASE to be highly sensitive and specific
for the detection of significant CAD by either criteria (88%
and 95%, respectively).
Level of confidence. We have previously validated the
reproducibility of the echocardiographic (29,30), coronary
angiographic (31) and cardiac scintigraphic (22) methods
used in this study at our institution. The level of confidence
for the interpretation of 87% (46 of 53) of the PASE studies
was high. Seven studies (13%) were interpreted with an
intermediate level of confidence, and no study was inter-
preted with a low level of confidence. This proportion is
similar to that ascribed to other imaging tests (5,32). In the
group of patients interpreted with a high level of confidence
for all three coronary vascular territories, the accuracy,
sensitivity and specificity rose to 97% for all.
Effect of pacing protocol. We used a modified and rapid
pacing protocol not only to shorten the duration of the test
and to improve tolerability, but also to induce an abrupt
increase in myocardial oxygen consumption. The increase in
myocardial oxygen consumption is due not only to the
increase in heart rate, but also to the increase in myocardial
contractility, which occurs as a consequence of the increased
heart rate (Bowditch-Treppe effect) (32–34). Using this
modified protocol, we were able to achieve .85% of the
age-predicted target heart rate in 94% of the patients, even
though a substantial number of patients (52%) were treated
with beta-receptor or calcium channel antagonists at the
time of PASE testing.
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The significant increase in heart rate, together with a
mild increase in systolic blood pressure in the majority of
our patients, resulted in a mean rate–pressure product that is
either equal to or higher than that induced by dobutamine/
atropine or exercise stress in previously published studies
(4,5,16,35,36). The rate–pressure product is known to be an
indirect index of the stress imposed on the heart. Thus,
PASE results in sufficient stress to accurately evaluate
inducible myocardial ischemia.
Study limitations. The patients in our study may have had
a high pretest likelihood of having CAD. However, 25% of
the patients had normal arteries or stenoses ,50% diameter
stenosis and 15% had single-vessel coronary disease. This
distribution is similar to that of previous reports (20) and is
representative of patients with new-onset chest pain, as we
did not exclude patients with baseline wall motion abnor-
malities or suboptimal echocardiographic images. No direct
comparison of PASE and DSE, or other methods of
pharmacologic stress echocardiography, was performed.
Conventional coronary angiographic interpretation was
used to identify the severity of CAD. The limitations of this
technique are well recognized (37–40). However, it is the
most commonly used method to interpret coronary angiog-
raphy (20). Consequently, assessment of the echocardio-
graphic results by this method is important for the gener-
alization of our findings to clinical practice. In addition, it is
important to note that, like any method of stress echocar-
diography, for accurate results, the cardiologist must be
meticulous to ensure that the sonographer performing the
studies obtains images so that at least 90% of the myocardial
segments can be interpreted with a high level of confidence.
Conclusions. Pacing stress echocardiography is accurate
for the detection of significant CAD in patients admitted to
the hospital with new-onset chest pain. Furthermore, the
test is well tolerated and feasible at the bedside. We believe
the safety of PASE is partly related to the ability to
immediately terminate pacing and stress-induced ischemia.
Thus, PASE may be used as a substitute for pharmacologic
DSE for rapid evaluation of inducible myocardial ischemia,
especially in patients who may be more unstable and who
could benefit from a method of stress that can be abruptly
terminated.
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